Sumitomo Pharma Co.Ltd.

As of March 31, 2025, Sumitomo Pharma Co Ltd. carries a market capitalization of 1.75B, placing it among publicly traded companies globally. Its enterprise value stands at 3.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sumitomo Pharma Co Ltd.'s next confirmed earnings release is scheduled for October 30, 2026.

As of March 31, 2025, Sumitomo Pharma Co Ltd. has 366.22M shares outstanding.

These figures are as of March 31, 2025.

As of March 31, 2025, Sumitomo Pharma Co Ltd. maintains a current ratio of 1.05, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2025.

Over the twelve months ended March 31, 2025, Sumitomo Pharma Co Ltd. recorded an income tax benefit of -138.06M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 19, 2026, Sumitomo Pharma Co Ltd.'s stock has gained approximately 11.79% over the past 52 weeks.

As of March 31, 2025, Sumitomo Pharma Co Ltd. holds 266.57M in cash and equivalents against 2.04B in total debt, resulting in a net debt position of 1.88B. Total book value stands at 1.13B, with working capital of 83.83M providing operational flexibility.

These figures cover the twelve months ended March 31, 2025.